Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Axsome Therapeutics	CytoDyn	Deciphera Pharmaceuticals	Prelude Therapeutics	Global Blood Therapeutics
Symbol	NASDAQ:AXSM	OTCMKTS:CYDY	NASDAQ:DCPH	NASDAQ:PRLD	NASDAQ:GBT
Price Information
Current Price	$52.99	$3.13	$43.81	$35.26	$40.77
52 Week Range	Buy	Hold	Buy	Hold	Buy
MarketRank™
Overall Score	1.4	1.1	1.6	1.4	1.4
Analysis Score	3.4	3.0	3.4	3.1	3.4
Community Score	2.7	2.6	2.5	1.7	3.0
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.8	0.0	1.7	1.7	0.0
Earnings & Valuation Score	0.0	0.0	0.6	0.6	0.6
Analyst Ratings
Consensus Recommendation	Buy	Hold	Buy	Hold	Buy
Consensus Price Target	$146.90	$4.00	$70.30	$54.25	$92.33
% Upside from Price Target	177.22% upside	27.80% upside	60.47% upside	53.86% upside	126.47% upside
Trade Information
Market Cap	$1.98 billion	$1.92 billion	$2.52 billion	$1.64 billion	$2.53 billion
Beta	2.59	-0.64	1.49	N/A	1.39
Average Volume	304,024	4,818,552	442,447	219,338	996,688
Sales & Book Value
Annual Revenue	N/A	N/A	$25 million	N/A	$2.11 million
Price / Sales	N/A	N/A	100.98	N/A	1,201.01
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$5.18 per share	($0.01) per share	$10.71 per share	N/A	$9.61 per share
Price / Book	N/A	N/A	4.09	N/A	4.24
Profitability
Net Income	$-68,350,000.00	$-124,400,000.00	$-192,260,000.00	N/A	$-266,770,000.00
EPS	($2.01)	($0.21)	($4.48)	N/A	($4.71)
Trailing P/E Ratio	N/A	N/A	N/A	0.00	N/A
Forward P/E Ratio	N/A	∞	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	N/A	N/A	-332.94%
Return on Equity (ROE)	-62.33%	N/A	-45.02%	N/A	-56.43%
Return on Assets (ROA)	-47.87%	-153.30%	-40.12%	N/A	-39.32%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.36%	5.01%	N/A	N/A	0.16%
Current Ratio	9.99%	1.13%	9.34%	20.96%	7.63%
Quick Ratio	9.99%	0.28%	9.26%	20.96%	7.20%
Ownership Information
Institutional Ownership Percentage	63.64%	0.10%	73.61%	76.21%	N/A
Insider Ownership Percentage	26.00%	7.80%	7.02%	N/A	4.30%
Miscellaneous
Employees	60	19	255	68	389
Shares Outstanding	37.41 million	612.83 million	57.63 million	46.59 million	62.16 million
Next Earnings Date	5/14/2021 (Estimated)	N/A	5/4/2021 (Estimated)	6/15/2021 (Estimated)	5/5/2021 (Estimated)
Optionable	Optionable	Not Optionable	Optionable	Not Optionable	Optionable

Source	Headline
	Shareholders Are Thrilled That The Global Blood Therapeutics (NASDAQ:GBT) Share Price Increased 101% finance.yahoo.com - April 9 at 8:50 AM
	Global Blood Therapeutics' Sickle Cell Med Results In Rapid, Durable Improvements In Hemoglobin Levels Throughout 72 Weeks Of Treatment finance.yahoo.com - April 8 at 2:03 PM
	Complete 72-Week Results from Phase 3 HOPE Study of Oxbryta® (voxelotor) Tablets Published in The Lancet Haematology Show Significantly Improved Hemoglobin, Hemolysis and Overall Health Status in Sickle Cell Disease Patients finance.yahoo.com - April 8 at 9:03 AM
	$43.24 Million in Sales Expected for Global Blood Therapeutics, Inc. (NASDAQ:GBT) This Quarter americanbankingnews.com - April 8 at 4:02 AM
	Global Blood Therapeutics (NASDAQ:GBT) Upgraded to Hold by Zacks Investment Research marketbeat.com - April 6 at 2:08 PM
	Financial Comparison: Dr. Reddy's Laboratories (NYSE:RDY) versus Global Blood Therapeutics (NASDAQ:GBT) americanbankingnews.com - April 4 at 12:10 PM
	Global Blood Therapeutics: Can This Biotech Still Disrupt The Sickle Cell Disease Space? finance.yahoo.com - April 4 at 8:39 AM
	Global Blood Therapeutics, Inc. (NASDAQ:GBT) Given Average Recommendation of "Buy" by Analysts americanbankingnews.com - April 1 at 12:52 PM
	Global Blood (GBT) Down 7.1% Since Last Earnings Report: Can It Rebound? finance.yahoo.com - March 26 at 3:10 PM
	Newron Pharmaceuticals (OTCMKTS:NWPHF) versus Global Blood Therapeutics (NASDAQ:GBT) Head-To-Head Comparison americanbankingnews.com - March 24 at 4:54 AM
	GBT Appoints Alexis A. Thompson, M.D., M.P.H., to Board of Directors finance.yahoo.com - March 18 at 8:25 AM
	Analysts Offer Insights on Healthcare Companies: Global Blood Therapeutics (GBT), Aprea Therapeutics (APRE) and Nabriva (NBRV) smarteranalyst.com - March 17 at 12:08 PM
	Wolfe Research Initiates Coverage on Global Blood Therapeutics (NASDAQ:GBT) americanbankingnews.com - March 17 at 11:35 AM
	Wolfe Research Begins Coverage on Global Blood Therapeutics (NASDAQ:GBT) marketbeat.com - March 17 at 8:35 AM
	Global Blood Therapeutics inks deal for two sickle cell disease drugs from Sanofi medcitynews.com - March 16 at 9:06 PM
	GBT Expands Sickle Cell Disease Pipeline with Exclusive In-license of Two Novel Small Molecule Programs from Sanofi S.A. finance.yahoo.com - March 16 at 11:05 AM
	GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference finance.yahoo.com - March 2 at 11:39 AM
	GBT Opens 2021 ACCEL Grant Program, Providing up to $500,000 in Support to the Sickle Cell Disease Community finance.yahoo.com - March 2 at 11:39 AM
	Black History and Biotechnology: A Conversation with Dr. Ted Love, President and CEO of Global Blood Therapeutics (GBT) bio.org - February 25 at 8:56 PM
	Global Blood (GBT) Q4 Earnings Miss, Revenues Beat Estimates nasdaq.com - February 25 at 3:56 PM
	Recap: Global Blood Therapeutics Q4 Earnings finance.yahoo.com - February 25 at 12:11 AM
	GBT Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results finance.yahoo.com - February 24 at 7:11 PM
	Preview: Global Blood Therapeutics's Earnings finance.yahoo.com - February 23 at 2:21 PM
	Global Blood Therapeutics (GBT) May Report Negative Earnings: Know the Trend Ahead of Q4 Release markets.businessinsider.com - February 18 at 8:14 AM
	GBT to Announce Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021 finance.yahoo.com - February 17 at 12:00 PM
	Is Global Blood Therapeutics (NASDAQ:GBT) A Risky Investment? finance.yahoo.com - February 8 at 9:08 AM
	GBT Initiates Expanded Access Protocol for Oxbryta(R) (voxelotor) in Pediatric Patients with Sickle Cell Disease in the United States marketwatch.com - February 5 at 9:57 AM

Date	Company	Brokerage	Action
3/8/2021	Axsome Therapeutics	Morgan Stanley	Boost Price Target
3/2/2021	Axsome Therapeutics	Mizuho	Lower Price Target
1/8/2021	Axsome Therapeutics	Jefferies Financial Group	Initiated Coverage
12/31/2020	Axsome Therapeutics	UBS Group	Reiterated Rating
12/3/2020	Axsome Therapeutics	Cantor Fitzgerald	Boost Price Target
10/1/2020	Axsome Therapeutics	William Blair	Reiterated Rating
9/29/2020	Axsome Therapeutics	Bank of America	Initiated Coverage
8/6/2020	Axsome Therapeutics	HC Wainwright	Reiterated Rating
4/28/2020	Axsome Therapeutics	Guggenheim	Boost Price Target
4/27/2020	Axsome Therapeutics	LADENBURG THALM/SH SH	Boost Price Target
4/27/2020	Axsome Therapeutics	SunTrust Banks	Boost Price Target
4/14/2020	Axsome Therapeutics	Cowen	Initiated Coverage
3/30/2021	Deciphera Pharmaceuticals	Credit Suisse Group	Initiated Coverage
2/10/2021	Deciphera Pharmaceuticals	Barclays	Lower Price Target
2/10/2021	Deciphera Pharmaceuticals	SVB Leerink	Upgrade
12/2/2020	Deciphera Pharmaceuticals	Stifel Nicolaus	Initiated Coverage
9/14/2020	Deciphera Pharmaceuticals	JPMorgan Chase & Co.	Initiated Coverage
5/7/2020	Deciphera Pharmaceuticals	Nomura Instinet	Downgrade
1/22/2020	Deciphera Pharmaceuticals	Piper Sandler	Reiterated Rating
1/21/2020	Deciphera Pharmaceuticals	Nomura Securities	Boost Price Target
1/15/2020	Deciphera Pharmaceuticals	JMP Securities	Reiterated Rating
12/20/2019	Deciphera Pharmaceuticals	Piper Jaffray Companies	Boost Price Target
10/20/2020	Prelude Therapeutics	The Goldman Sachs Group	Initiated Coverage
3/17/2021	Global Blood Therapeutics	Wolfe Research	Initiated Coverage
12/3/2020	Global Blood Therapeutics	Royal Bank of Canada	Initiated Coverage
11/9/2020	Global Blood Therapeutics	Truist	Lower Price Target
11/6/2020	Global Blood Therapeutics	Canaccord Genuity	Lower Price Target
11/6/2020	Global Blood Therapeutics	Roth Capital	Lower Price Target
11/6/2020	Global Blood Therapeutics	Oppenheimer	Lower Price Target
11/6/2020	Global Blood Therapeutics	Raymond James	Downgrade
10/6/2020	Global Blood Therapeutics	Evercore ISI	Initiated Coverage
8/25/2020	Global Blood Therapeutics	Wedbush	Boost Price Target

(Data available from 4/10/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources